Recent Advances in Pain Management: Relevant Protein Kinases and Their Inhibitors

Francis Giraud; Elisabeth Pereira; Fabrice Anizon; Pascale Moreau

doi:10.3390/molecules26092696

Recent Advances in Pain Management: Relevant Protein Kinases and Their Inhibitors

Molecules. 2021 May 4;26(9):2696. doi: 10.3390/molecules26092696.

Authors

Francis Giraud¹, Elisabeth Pereira¹, Fabrice Anizon¹, Pascale Moreau¹

Affiliation

¹ Université Clermont Auvergne, CNRS, Clermont Auvergne INP, ICCF, F-63000 Clermont-Ferrand, France.

Abstract

The purpose of this review is to underline the protein kinases that have been established, either in fundamental approach or clinical trials, as potential biological targets in pain management. Protein kinases are presented according to their group in the human kinome: TK (Trk, RET, EGFR, JAK, VEGFR, SFK, BCR-Abl), CMGC (p38 MAPK, MEK, ERK, JNK, ASK1, CDK, CLK2, DYRK1A, GSK3, CK2), AGC (PKA, PKB, PKC, PKMζ, PKG, ROCK), CAMK, CK1 and atypical/other protein kinases (IKK, mTOR). Examples of small molecule inhibitors of these biological targets, demonstrating an analgesic effect, are described. Altogether, this review demonstrates the fundamental role that protein kinase inhibitors could play in the development of new pain treatments.

Keywords: inhibitors; pain; protein kinases.

Publication types

Review

MeSH terms

Animals
Humans
Pain Management*
Protein Kinase Inhibitors / chemistry
Protein Kinase Inhibitors / therapeutic use*
Protein Kinases / metabolism*
Structure-Activity Relationship

Substances

Protein Kinase Inhibitors
Protein Kinases